Chronic Pain in COVID-19 Patients Discharged From Intensive Care Unit
CompletedNCT04940208
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
More than six million French were affected by SARS-COV2 epidemic. About 20% of infected peoples were hospitalized, and about 5% were admitted to the intensive care units (ICU) for severe SARS-COV2 acute respiratory distress syndrome (ARDS) management. A spectrum of neuropsychiatric sequelae, specific for the ICU exposure, was already described, including post-intensive care syndrome and persistent pain. A growing body of evidence suggests the impact of SARS-COV2 exposure on the occurrence of neurological disorders and chronic pain syndrome development in COVID-19 patients. Taking together, one can expect a large number of patients discharged from ICU after severe COVID-19 with high prevalence of persistent pain and psychological disorders. To date, no study has evaluated neither the incidence of persistant pains in ICU COVID-19 survivors, nor pain phenotypes. The knowledge of such data is crucial in order to anticipate the management of such patients by specialized pain team, and to quantify the possible incurred burden of care. Our study aims to evaluate the incidence of pain, pain localization and severity, associated pain-related psychological disorders, and to perform quantitative sensory testing in severe COVID-19 patients, admitted to the ICU for more than 48 hours and successfully discharged home during the first French pandemic wave.
Study details
- Official title
- Chronic Pain in COVID-19 Patients Discharged From Intensive Care Unit - a Multicenter Observational Cohort Study
- Conditions
- COVID-19 Pandemic
- ICU
- Pain, Chronic
- Post Intensive Care Unit Syndrome
- Neuropathic Pain
- Interventions
- Other: Pain and neuropsychological questionnaires
- Diagnostic test: Quantitative Sensory testing
- Sponsor
- Mikhail Dziadzko, MD, PhD
- Collaborators
- Hôpital Raymond Poincaré; Bicetre Hospital
- Organization
- Hôpital de la Croix-Rousse
- Start date
- 2021-01-11
- Primary completion
- 2022-01-01
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- France
- Total sites listed
- 3
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * adults (\>=18 y.o.) * hospitalized in the ICU for at least 48 hours * with SARS-Cov2 infection confirmed by Polymerase Chain Reaction (PCR)/serology and/or a suggestive chest Computed Tomography scan * during the first wave of COVID 19 from March to December 2020 at three investigator sites (2 in Paris and 1 in Lyon) * discharged alive from the ICU * at least 6 months after discharge Exclusion Criteria: * patient refusal * inability to communicate or to have in-person appointment * death in the period from ICU discharge to the first phone call for interview
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04940208